Shiv Srivastava

OverviewAI-generated summary

Shiv Srivastava's research focuses on prostate cancer, investigating its genetic underpinnings, diagnostic biomarkers, and potential therapeutic targets. His work includes the identification of novel susceptibility variants for prostate cancer, particularly within populations of African ancestry, and the development of polygenic risk scores to assess aggressive disease risk. Srivastava has explored the prognostic significance of protein expression, such as p53, and lymphovascular invasion in predicting metastatic progression in primary prostate tumors.

Further research areas include the clinical utility of multiparametric MRI and immunohistochemistry in predicting biochemical recurrence after radical prostatectomy, as well as the characterization of germline mutations in DNA damage repair genes within African American men diagnosed with prostate cancer. Srivastava has also contributed to the development of selective inhibitors targeting ERG-positive prostate cancer. His broader interests extend to the molecular mechanisms of apoptosis, with publications examining the inhibition of BAK-mediated apoptosis by BH3-only proteins and the structural basis of BAK sequestration by MCL-1.

Srivastava's scholarly output is substantial, evidenced by an h-index of 64 and over 490 publications with more than 15,000 citations. He has collaborated with researchers including Steve Lee and Elisabeth Ferreira at the University of Arkansas for Medical Sciences, and Bin Dong at the University of Arkansas at Fayetteville.

Metrics

• h-index: 64
• Publications: 490
• Citations: 15,057